NattoPharma to introduce first full-spectrum vitamin K2

41b65b18-2db6-4664-8ef0-56992dc210d7articleimage.jpg

22 Sep 2017 --- NattoPharma is set to launch MenaQ7 Full Spectrum K2. This latest innovation is the result of a proprietary technological breakthrough, creating a vitamin K2 that provides menaquinones (MK) 6, 7, 8 and 9, a range of isomers vital for cardiovascular health, the company reports. 

“NattoPharma has driven the creation of the vitamin K2 market, sponsoring the important research validating the importance of K2 for human health, and this work has shaped the MenaQ7 brand,” says NattoPharma Chief Medical Officer Dr. Hogne Vik. 

“The important epidemiological studies that led us to our ground-breaking human clinical research used fermented cheese as the source of vitamin K2, which led us to create MenaQ7 Full Spectrum,” Vik adds.

According to researchers closely linked to these epidemiological studies: “Vitamin K is a fat-soluble vitamin that plays and unequivocal role in the activation of Gla-proteins. Although all K-vitamins have the same function, they differ in bioavailability and bioactivity.”

“The Rotterdam and Prospect studies have shown that food-derived vitamin K (such as from cheeses) improves long-term cardiovascular health outcomes because it more specifically delivers the long-chain menaquinones MK-6, 7, 8 and 9,” they add.

“While fermented cheeses are the best dietary source of menaquinones in the West, most will not be able to consume enough to obtain optimal amounts of Vitamin K2, nor is cheese a practical source for extracting the menaquinones,” adds Dr. Vik. “To that end, NattoPharma has once again broken the mold and offers to the market a raw material that delivers the range of menaquinones found in foods.”

The first and only vitamin K2 to deliver to deliver a gamut of menaquinone isomers, MenaQ7 Full Spectrum is naturally fermented using chickpea protein, offering an all-trans vitamin K2 that is free from gluten, soy and all-known allergens, and is suitable for vegans and vegetarians. MenaQ7 Full Spectrum provides the vital menaquinone isomers MK-6, 7, 8 and 9 for optimal and maximal delivery of vitamin K2 with respect to absorption, half-life and biological activity.


“NattoPharma has once again created a raw material that speaks directly the natural dietary supplement consumer, who is drawn to comprehensive nutritional sources,” says Daniel Rosenbaum, NattoPharma CEO. “We welcome the opportunity to meet with companies at this year’s SupplySide West to officially launch this market-changing innovation.” 

MenaQ7 Full Spectrum Vitamin K2 will be launched at NattoPharma’s SupplySide West booth P115. 

In an earlier interview with NutritionInsight, Eric Anderson, Senior Vice President of Global Marketing and Business Development at NattoPharma, underlined the company’s commitment to supporting research into the benefits of vitamin K.

“When we look at vitamin K2 as menaquinone-7, we believe this is everything that is good about the natural products industry,” Anderson says. “Researchers discovered K2, and NattoPharma supported its substantiation. MenaQ7 was proven in healthy populations, and today NattoPharma is involved in two clinical trials with patients: a study of patients with coronary calcification; and a second study with patients who have aortic calcification.” 

“We’ve invested tens of millions of euros proving, with universities and independent researchers, that populations that eat a lot of a certain food with this micronutrient, which can also be taken as a supplement, are getting these health benefits,” Anderson says.

“We’re only supplying the active, menaquinone/vitamin K2; these studies are being paid for by traditional medical doctors who are treating diseased patients and the only active is a vitamin. And that’s what it really should be about: You have science, science leads to discovery, which in turn leads to an investment into proving that [an active] works as a dietary supplement,” Anderson says.

References:
1 Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004;134:3100-5.
2 Beulens JW, Bots ML, Atsma F, et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2009;203:489-93.
3 Gast GC, de Roos NM, Sluijs I, et al. A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis. 2009;19:504-10.

To contact our editorial team please email us at editorial@cnsmedia.com

NattoPharma ASA

Collapse

As the leader in Vitamin K2 research & development, NattoPharma has not only created the Vitamin K2 category, but continues to drive it forward. Offering the best and first clinically validated and patented Vitamin K2 as MK-7 on the market, MenaQ7®, NattoPharma has sponsored the groundbreaking research that has confirmed K2’s essential role in bone and cardiovascular health, for old and young alike.

NattoPharma’s mission is to advance global health by creating and introducing to the market scientifically validated products and technologies that will deliver measurable health benefits and optimal health outcomes.

This mission is accomplished by:

• Addressing significant health concerns with branded, scientifically validated, proprietary products and technologies, leading with our flagship brand MenaQ7®;

• Leveraging all manner of technology to more effectively and efficiently deliver these products to our target markets;

• Solidifying ourselves as the experts in the science underlying our products and associated enabling technologies that allow us to effectively deliver them to the marketplace; and

• Developing and maintaining a deep customer and segment understanding of the benefits we deliver.

With 19+ published studies and even more underway, NattoPharma has an unparalleled patent portfolio related to relevant health benefits and market segments, creating extra values for its customers.  

MenaQ7® meets the growing demand for highly pure, stable K2 for supplemental and food use in any different format.

The most comprehensive Vitamin K2 ingredient portfolio meeting market needs:

MenaQ7® Natural MK-7: 96% pure all-trans MK-7 free of soy and other allergens.

MenaQ7® PharmaPure MK-7: The only all-trans nature-identical synthetic, winner of 2015   NutrAward for Best Functional Ingredient

MenaQ7® Natto MK-7: 96% active all-trans soy fermented MK-7

MenaQ7® Full Spectrum K2: The first and only K2 to deliver menaquinone isomers MK-6, 7, 8, and 9, free from soy and other allergens.

All material is available with CryoCap microencapsulation, ensuring stable menaquinone protection in any formulation.

The MenaQ7® brand is built upon 6 Pillars of Excellence, a platform delivering the most safe and efficacious Vitamin K2 on the market, creating opportunities for manufacturers and value for end users:

• Trusted Expertise

• Science Leader

• Superior Products

• Continuous Innovation

• Educational Marketing

• Cooperative Support

Visit website for more information: www.menaq7.com 

Related Articles

Nutrition & Health News

Weekly Digest: NP Nutra triples its warehouse space, broccoli named US top vegetable

15 Jun 2018 --- This week in nutrition, research studies affirmed the benefit of vitamin K2 for healthy bones, vitamin E tocotrienol may delay paralysis associated with Alzheimers and vegetables took center stage in the US with a survey identifying broccoli as the nations favorite and large investments were made in school plant-based cafeteria options. At a sports nutrition conference, Nitrosamines positive effects on cognitive function were announced, while National Institutes of Health launched a new app aimed at providing safe information on popular herbs. Concerning expansions, NP Nutra expanded its warehouse in California and Azelis opened a new pharmaceutical manufacturing facility in Germany.

Nutrition & Health News

Weekly Digest: Plant-based diet boosts healthy hearts, GMP registration for OmniActive health ingredients plant

08 Jun 2018 --- This week in nutrition, OmniActive has had its Hosur plant, that manufactures natural extracts, gain Good Manufacturing Practice (GMP) from NSF and Omya International had its orally disintegrating tablets confirmed by a scientific study. The benefits of a plant-based diet for a healthy heart were touted by researchers, including lower cholesterol and blood pressure. Lastly, NattoPharma and its pharmaceutical spin-off Kaydence Pharma appointed new CEO's amid positive growth results and Lycored appoints a new SVP as it seeks to grow R&D capabilities.

Nutrition & Health News

NattoPharma spearheads vitamin K2 RDI program

04 Jun 2018 --- Norway-based biotech company NattoPharma has enlisted its research partners to start a program to establish what the company says is a much-needed Recommended Daily Intake (RDI) for vitamin K2. 

Nutrition & Health News

One gram of fish oil a day to keep osteoarthritis pain at bay, study suggests

10 May 2018 --- One gram of fish oil a day could help reduce the pain of patients with osteoarthritis, a new study in Rheumatology reports. In the largest, most up to date study of its kind, researchers from the University of Surrey examined the link between diet and the effective self-management of osteoarthritis.

Nutrition & Health News

MenaQ7 Full Spectrum K2 closest ingredient to dietary cheese intake, study finds

20 Apr 2018 --- Based on a global state of vitamin K2 deficiency and the strong evidence showing it is a cardio-protective nutrient, researchers recommend cheese as a component of a heart-healthy diet due to its vitamin K2 content. However, for those unable to consume enough cheese daily, NattoPharma has introduced its MenaQ7 Full Spectrum K2, which aims to deliver the range of menaquinones found in foods.

More Articles
URL : http://www.nutritioninsight.com:80/news/nattopharma-to-introduce-first-full-spectrum-vitamin-k2.html